PACS Group (PACS) has just posted Q1 2026 revenue of about US$1.4 billion and basic EPS of US$0.51, setting the tone for the new financial year with higher reported earnings versus the same quarter last year. Over recent quarters the company has seen revenue move from US$1,277.2 million in Q1 2025 to US$1,420.5 million in Q1 2026, while basic EPS has shifted from US$0.18 to US$0.51. This gives investors a clearer read on how higher profitability is feeding through the income statement. With trailing net profit margins now above last year’s level, this set of results puts the focus squarely on how durable these margin gains might be.

See our full analysis for PACS Group.

With the quarterly numbers on the table, the next step is to see how this earnings profile lines up with the most common narratives you hear about PACS Group and where those stories might need updating.

Net income climbs to US$80.7 million

• Net income excluding extra items sits at US$80.7 million for Q1 2026, compared with US$59.7 million in Q4 2025 and US$28.5 million in Q1 2025, while trailing twelve month net income is US$243.8 million on US$5.4b of revenue.
• Supporters of the bullish view point to this trailing twelve month earnings of US$243.8 million against last year’s US$49.4 million as evidence that PACS is already operating closer to the higher margin profile they expect, yet the jump in profitability is coming while roughly one third of facilities are described as newer, lower margin cohorts. This means:
  • The bullish claim that improving newly acquired facilities could lift consolidated margins further is consistent with the move in trailing net profit margin from 1.1% to 4.5% on US$5.4b of revenue.
  • At the same time, the earlier rapid expansion into over 100 facilities raises the risk in that bullish story if integration costs or slower operational ramp keep newer sites from closing the gap with mature facilities.

On the back of this much higher profit base, bulls argue there could still be more room for margin improvement if new facilities catch up to mature sites, and the full bullish thesis is set out in 🐂 PACS Group Bull Case.

Margins and growth vs rich P/E

• Trailing net profit margin of 4.5% on US$5.4b of revenue sits alongside a P/E of 26.6x versus 22.7x for the US Healthcare industry and 22.2x for peers, and a DCF fair value of US$59.00 compared with a current share price of US$41.01.
• Skeptical, more bearish views focus on the combination of that 26.6x P/E and recent share price volatility, arguing the stock already prices in strong execution. Yet the data here show:
  • The P/E premium over industry and peers contrasts with a DCF fair value that is above the current price, which gives investors two different signals to weigh against each other.
  • Recent insider selling, flagged alongside that volatility, fits with a cautious stance, even as trailing earnings per share on a twelve month basis is US$1.56, well above the US$0.32 level a year earlier.

If you are weighing whether the earnings strength balances the higher P/E and recent insider selling, the more cautious side of the story is laid out in 🐻 PACS Group Bear Case.

Revenue base supports higher EPS

• On a trailing basis, PACS has generated US$5.4b in revenue and US$1.56 in basic EPS, compared with trailing revenue of US$4.4b and basic EPS of US$0.32 a year earlier, while quarterly revenue has stepped from US$1,277.2 million in Q1 2025 to US$1,420.5 million in Q1 2026.
• Consensus style expectations that earnings could grow at about 18% per year with revenue growing about 7.4% per year rest on the idea that this larger revenue base can support further profitability gains, and the figures here give you reference points:
  • Trailing twelve month earnings growth is described as very large at 393.3% year over year, set against more moderate forward growth expectations, so investors may question whether future years resemble the recent surge or the steadier forecasts.
  • Analyst assumptions that profit margins could rise from 3.3% to 10.9% over several years are being compared with today’s 4.5% trailing margin, so the current level is only partway toward that longer term margin narrative.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for PACS Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards on the table, the key question is how you weigh them for yourself. Move quickly from headlines to the underlying numbers and judge whether the balance of 3 key rewards and 2 important warning signs

See What Else Is Out There

Despite its earnings momentum, PACS Group still trades at a relatively high 26.6x P/E, with insider selling and a margin outlook that depends heavily on future execution.

If you are looking for alternatives where pricing appears less demanding right now, use the 45 high quality undervalued stocks to quickly identify stocks that may offer a more comfortable entry point.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.